BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

NEW YORK, Dec. 26, 2023 /PRNewswire/ — Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes….